Cannabis Ruderalis

thcscience_admin
LY-2183240
Names
IUPAC name
N,N-dimethyl-5-[(4-biphenyl)methyl]tetrazole-1-carboxamide
Identifiers
3D model (JSmol)
ECHA InfoCard 100.189.657 Edit this at Wikidata
  • CN(C)C(=O)n1nnnc1Cc2ccc(cc2)-c3ccccc3
Properties
C17H17N5O
Molar mass 307.349
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

LY-2183240 is a drug which acts both as a potent inhibitor of the reuptake of the endocannabinoid anandamide, and as an inhibitor of fatty acid amide hydrolase (FAAH), the primary enzyme responsible for degrading anandamide. This leads to markedly elevated anandamide levels in the brain, and LY-2183240 has been shown to produce both analgesic and anxiolytic effects in animal models.[1][2][3][4]

See also

References

  1. ^ Dickason-Chesterfield AK, Kidd SR, Moore SA, Schaus JM, Liu B, Nomikos GG, Felder CC. Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors. Cellular and Molecular Neurobiology. 2006 Jul-Aug;26(4-6):407-23. PMID 16736384
  2. ^ Alexander JP, Cravatt BF. The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. Journal of the American Chemical Society. 2006 Aug 2;128(30):9699-704. PMID 16866524
  3. ^ Maione S, Morera E, Marabese I, Ligresti A, Luongo L, Ortar G, Di Marzo V. Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: cannabinoid and non-cannabinoid receptor-mediated mechanisms. British Journal of Pharmacology. 2008 Nov;155(5):775-82. PMID 18660824
  4. ^ Powers MS, Barrenha GD, Mlinac NS, Barker EL, Chester JA. Effects of the novel endocannabinoid uptake inhibitor, LY2183240, on fear-potentiated startle and alcohol-seeking behaviors in mice selectively bred for high alcohol preference. Psychopharmacology (Berlin). 2010 Dec;212(4):571-83. PMID 20838777

1. Moore SA, Nomikos GG, Dickason-Chesterfield AK, Schober DA, Schaus JM, Ying BP, Xu YC, Phebus L, Simmons RM, Li D, Iyengar S, Felder CC. Identification of a high-affinity binding site involved in the transport of endocannabinoids. 2005 Dec; 102(49):17852-7. PMID 16314570 

2.Jump up ^ Dickason-Chesterfield AK, Kidd SR, Moore SA, Schaus JM, Liu B, Nomikos GG, Felder CC. Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors. Cellular and Molecular Neurobiology. 2006 Jul-Aug;26(4-6):407-23. PMID 16736384
3.Jump up ^ Alexander JP, Cravatt BF. The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. Journal of the American Chemical Society. 2006 Aug 2;128(30):9699-704. PMID 16866524
4.Jump up ^ Maione S, Morera E, Marabese I, Ligresti A, Luongo L, Ortar G, Di Marzo V. Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: cannabinoid and non-cannabinoid receptor-mediated mechanisms. British Journal of Pharmacology. 2008 Nov;155(5):775-82. PMID 18660824
5.Jump up ^ Powers MS, Barrenha GD, Mlinac NS, Barker EL, Chester JA. Effects of the novel endocannabinoid uptake inhibitor, LY2183240, on fear-potentiated startle and alcohol-seeking behaviors in mice selectively bred for high alcohol preference. Psychopharmacology (Berlin). 2010 Dec;212(4):571-83. PMID 20838777
source: https://en.wikipedia.org/w/index.php?title=LY-2183240&oldid=577335735

Leave a Reply